<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40659197</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-6744</ISSN><JournalIssue CitedMedium="Internet"><Volume>290</Volume><PubDate><Year>2025</Year><Month>Dec</Month></PubDate></JournalIssue><Title>American heart journal</Title><ISOAbbreviation>Am Heart J</ISOAbbreviation></Journal><ArticleTitle>The effects of low-dose colchicine on the progression of aortic valve stenosis: Rationale, design, and baseline characteristics of the Colchicine and Inflammation in Aortic Stenosis (CHIANTI) trial.</ArticleTitle><Pagination><StartPage>297</StartPage><EndPage>309</EndPage><MedlinePgn>297-309</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ahj.2025.07.010</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0002-8703(25)00219-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Aortic valve stenosis (AS) is one of the most common valvular heart diseases worldwide. Its prevalence increases with age and is expected to rise further as the population ages. Untreated severe AS carries a 2-year mortality rate exceeding 50%. Furthermore, surveillance and management of AS impose a significant burden on healthcare systems. Therefore, effective pharmacological strategies are urgently needed to slow or halt the progression of AS.</AbstractText><AbstractText Label="RATIONALE AND DESIGN" NlmCategory="METHODS">Inflammation plays a central role in the pathogenesis of both atherosclerosis and AS. Anti-inflammatory therapy with low-dose colchicine reduces cardiovascular events in patients with coronary artery disease, but its efficacy has not been tested in AS. Colchicine and Inflammation in Aortic Stenosis (CHIANTI) is an investigator-initiated, placebo-controlled, double-blind, multicenter, randomized trial involving 150 patients with moderate AS. After confirming tolerance during a two-week run-in phase, eligible participants underwent coronary computed tomography (CT) angiography, <sup>18</sup>F-sodium fluoride (<sup>18</sup>F-NaF) positron emission tomography (PET)-CT, and echocardiography. Thereafter, participants were randomized 1:1 to colchicine 0.5 mg once daily or a matching placebo. All baseline imaging is repeated after 24 months. The primary endpoint is the change in aortic valve calcium score on CT. Secondary endpoints are (1) the change in aortic valve <sup>18</sup>F-NaF uptake on PET-CT and corrected for target-to-background ratio, and (2) the change in peak aortic jet velocity on echocardiography.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The CHIANTI trial evaluates whether anti-inflammatory therapy with low-dose colchicine can slow or halt the progression of moderate AS. If successful, it would offer the first effective pharmacological treatment for AS.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">Registered on ClinicalTrials.gov (https://clinicaltrials.gov/), ID: NCT05162742.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mohammadnia</LastName><ForeName>Niekbachsh</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vestjens</LastName><ForeName>Lucas T W</ForeName><Initials>LTW</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Craig</LastName><ForeName>Neil J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Edinburgh Heart Centre, Royal Infirmary of Edinburgh, Edinburgh, UK; The University of Edinburgh Centre for Cardiovascular Science, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tijssen</LastName><ForeName>Jan G P</ForeName><Initials>JGP</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Amsterdam UMC, Location AMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knol</LastName><ForeName>Remco J J</ForeName><Initials>RJJ</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Northwest Clinics, Alkmaar, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazarenko</LastName><ForeName>Sergiy V</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Northwest Clinics, Alkmaar, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duffels</LastName><ForeName>Mari&#xeb;lle G J</ForeName><Initials>MGJ</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Northwest Clinics, Alkmaar, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaspers Focks</LastName><ForeName>Jeroen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Slingeland Ziekenhuis, Doetinchem, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hemels</LastName><ForeName>Martin E W</ForeName><Initials>MEW</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Cardiology, Rijnstate Ziekenhuis, Arnhem, The Netherlands; Dutch Network for Cardiovascular Research, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oving</LastName><ForeName>Iris</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Canisius Wilhelmina Ziekenhuis, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schalkx</LastName><ForeName>Hanke J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Radiology, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eikelboom</LastName><ForeName>John W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada; Hamilton Health Sciences, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cetinyurek-Yavuz</LastName><ForeName>Aysun</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>IQ Health, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aarntzen</LastName><ForeName>Erik H J G</ForeName><Initials>EHJG</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dey</LastName><ForeName>Damini</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Biomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slomka</LastName><ForeName>Piotr J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Departments of Medicine and Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nijveldt</LastName><ForeName>Robin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riksen</LastName><ForeName>Niels P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Royen</LastName><ForeName>Niels</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honigberg</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA; Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA; Heart and Vascular Institute, Massachusetts General Brigham, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dweck</LastName><ForeName>Marc R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Edinburgh Heart Centre, Royal Infirmary of Edinburgh, Edinburgh, UK; The University of Edinburgh Centre for Cardiovascular Science, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cornel</LastName><ForeName>Jan H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Cardiology, Northwest Clinics, Alkmaar, The Netherlands; Dutch Network for Cardiovascular Research, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El Messaoudi</LastName><ForeName>Saloua</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: Saloua.ElMessaoudi@radboudumc.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05162742</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am Heart J</MedlineTA><NlmUniqueID>0370465</NlmUniqueID><ISSNLinking>0002-8703</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>SML2Y3J35T</RegistryNumber><NameOfSubstance UI="D003078">Colchicine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003078" MajorTopicYN="Y">Colchicine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001024" MajorTopicYN="Y">Aortic Valve Stenosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001021" MajorTopicYN="Y">Aortic Valve</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="Y">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072078" MajorTopicYN="N">Positron Emission Tomography Computed Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004452" MajorTopicYN="N">Echocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017023" MajorTopicYN="N">Coronary Angiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="Y">Inflammation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of interest P.J.S. receives Cedars-Sinai software royalties, APQ health equity, and consulting fees from Synektik and Novo Nordisk. M.C.H. reports consulting fees (modest) from Comanche Biopharma, serves as a site principal investigator for Novartis, and receives research support from Genentech. All other authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>8</Day><Hour>8</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>15</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>14</Day><Hour>19</Hour><Minute>35</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40659197</ArticleId><ArticleId IdType="doi">10.1016/j.ahj.2025.07.010</ArticleId><ArticleId IdType="pii">S0002-8703(25)00219-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>